Cognition Therapeutics, Inc.
- Jurisdiction
United States - ISIN
US19243B1026 (CGTX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Read full profile
Stock price
Fundamentals
- Net revenue
€0.00 - Gross margin
0.0% - EBIT
-€45.15M - EBIT margin
0.0% - Net income
-€28.14M - Net margin
0.0%
Statement period: - (published )
Dividends
No dividend payouts
Earnings Calls
Latest earnings call: March 26, 2024
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Sell |